|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-6-3
|
|
pubmed:abstractText |
European studies provide a preponderance of evidence for sublingual allergen immunotherapy (SLIT) safety and efficacy, but they use allergen products that differ from those expected to be approved in the United States.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1081-1206
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
100
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
475-81
|
|
pubmed:dateRevised |
2008-11-13
|
|
pubmed:meshHeading |
pubmed-meshheading:18517081-Administration, Oral,
pubmed-meshheading:18517081-Administration, Sublingual,
pubmed-meshheading:18517081-Adolescent,
pubmed-meshheading:18517081-Adult,
pubmed-meshheading:18517081-Allergens,
pubmed-meshheading:18517081-Animals,
pubmed-meshheading:18517081-Asthma,
pubmed-meshheading:18517081-Cats,
pubmed-meshheading:18517081-Dermatophagoides farinae,
pubmed-meshheading:18517081-Desensitization, Immunologic,
pubmed-meshheading:18517081-Female,
pubmed-meshheading:18517081-Hair,
pubmed-meshheading:18517081-Humans,
pubmed-meshheading:18517081-Male,
pubmed-meshheading:18517081-Middle Aged,
pubmed-meshheading:18517081-Patient Compliance,
pubmed-meshheading:18517081-Patient Dropouts,
pubmed-meshheading:18517081-Pollen,
pubmed-meshheading:18517081-Rhinitis, Allergic, Perennial,
pubmed-meshheading:18517081-Rhinitis, Allergic, Seasonal,
pubmed-meshheading:18517081-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
|
|
pubmed:affiliation |
Research and Development, Greer Laboratories, Lenoir, North Carolina 28645, USA. esch@greerlabs.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
